191 related articles for article (PubMed ID: 38289962)
1. Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer.
Yu Z; Deng P; Chen Y; Lin D; Liu S; Hong J; Guan P; Chen J; Zhong ME; Chen J; Chen X; Sun Y; Wang Y; Wang P; Cai Z; Chan JY; Huang Y; Xiao R; Guo Y; Zeng X; Wang W; Zou Y; Yu Q; Lan P; Teh BT; Wu X; Tan J
Proc Natl Acad Sci U S A; 2024 Feb; 121(6):e2304619121. PubMed ID: 38289962
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
Okuyama T; Sameshima S; Takeshita E; Yoshioka R; Yamagata Y; Ono Y; Tagaya N; Noie T; Oya M
World J Surg Oncol; 2018 Jun; 16(1):105. PubMed ID: 29871650
[TBL] [Abstract][Full Text] [Related]
3. Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
Flatmark K; Saelen MG; Hole KH; Abrahamsen TW; Fleten KG; Hektoen HH; Redalen KR; Seierstad T; Dueland S; Ree AH
Radiother Oncol; 2016 Jun; 119(3):505-11. PubMed ID: 26968754
[TBL] [Abstract][Full Text] [Related]
4. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
5. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
[TBL] [Abstract][Full Text] [Related]
6. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer (NECI Study): a protocol for a phase II study.
Fan Y; Zhu X; Xu C; Ding C; Hu J; Hong Q; Wang J
BMJ Open; 2023 Mar; 13(3):e069401. PubMed ID: 36914193
[TBL] [Abstract][Full Text] [Related]
8. Preoperative chemoradiotherapy using tegafur/uracil, oral leucovorin, and irinotecan (TEGAFIRI) followed by oxaliplatin-based chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: the study protocol for a phase II trial.
Abe S; Kawai K; Nozawa H; Sasaki K; Murono K; Emoto S; Yokoyama Y; Matsuzaki H; Nagai Y; Yoshioka Y; Shinagawa T; Sonoda H; Yamamoto Y; Oba K; Ishihara S
BMC Cancer; 2023 May; 23(1):450. PubMed ID: 37198556
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
[TBL] [Abstract][Full Text] [Related]
11. Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.
Kim JK; Marco MR; Roxburgh CSD; Chen CT; Cercek A; Strombom P; Temple LKF; Nash GM; Guillem JG; Paty PB; Yaeger R; Stadler ZK; Gonen M; Segal NH; Reidy DL; Varghese A; Shia J; Vakiani E; Wu AJ; Romesser PB; Crane CH; Gollub MJ; Saltz L; Smith JJ; Weiser MR; Patil S; Garcia-Aguilar J
Oncologist; 2022 May; 27(5):380-388. PubMed ID: 35278070
[TBL] [Abstract][Full Text] [Related]
12. Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer.
Li ZY; Wang XD; Li M; Liu XJ; Ye Z; Song B; Yuan F; Yuan Y; Xia CC; Zhang X; Li Q
World J Gastroenterol; 2020 May; 26(19):2388-2402. PubMed ID: 32476800
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
Zhao L; Liu R; Zhang Z; Li T; Li F; Liu H; Li G
Colorectal Dis; 2016 Aug; 18(8):763-72. PubMed ID: 27169752
[TBL] [Abstract][Full Text] [Related]
14. Improved response rate in patients with prognostically poor locally advanced rectal cancer after treatment with induction chemotherapy and chemoradiotherapy when compared with chemoradiotherapy alone: A matched case-control study.
Voogt ELK; Schaap DP; van den Berg K; Nieuwenhuijzen GAP; Bloemen JG; Creemers GJ; Willems J; Cnossen JS; Peulen HMU; Nederend J; van Lijnschoten G; Burger JWA; Rutten HJT
Eur J Surg Oncol; 2021 Sep; 47(9):2429-2435. PubMed ID: 34030921
[TBL] [Abstract][Full Text] [Related]
15. Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer in Elderly Patients: Toxicity, Disease Control, and Survival Outcomes.
De Felice F; Llange K; Rubini F; Bulzonetti N; Caiazzo R; Musio D; Tombolini V
Clin Colorectal Cancer; 2018 Mar; 17(1):e77-e81. PubMed ID: 29113729
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal Cancer (PerSeUS-RC01).
Matsuhashi N; Takahashi T; Tanaka C; Yawata K; Yamada M; Iwata Y; Kiyama S; Mizutani C; Tajima JY; Ishihara T; Yoshida K
Anticancer Res; 2021 Dec; 41(12):6247-6257. PubMed ID: 34848480
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
Miwa K; Oki E; Enomoto M; Ihara K; Ando K; Fujita F; Tominaga M; Mori S; Nakayama G; Shimokawa M; Saeki H; Baba H; Mori M; Akagi Y
BMC Cancer; 2021 Jan; 21(1):23. PubMed ID: 33402130
[TBL] [Abstract][Full Text] [Related]
18. Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.
Chang H; Tao YL; Jiang W; Chen C; Liu SL; Ye WJ; Gao YH
BMC Cancer; 2020 Jun; 20(1):498. PubMed ID: 32487091
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer.
Fu XL; Fang Z; Shu LH; Tao GQ; Wang JQ; Rui ZL; Zhang YJ; Tian ZQ
Oncotarget; 2017 May; 8(21):34340-34351. PubMed ID: 28423720
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
Zhang W; Zhou H; Jiang J; Zhu Y; Zou S; Jiang L; Tang Y; Liang J; Sun Y; Jiang Z; Qu W; Li Y; Zhou A
BMC Cancer; 2023 Jun; 23(1):592. PubMed ID: 37370032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]